posted on 2021-06-29, 19:07authored byHuibin Lin, Liyuan Lin, Yahui Du, Juan Gao, Chaoyong Yang, Wei Wang
By catalyzing a 3–3 cross-link
in peptidoglycan, l,d-transpeptidases (Ldts) can
cause resistance to β-lactams
in some pathogens in vitro. However, the prevalence
of Ldt and Ldt-mediated responses to different β-lactams in vivo have never been explored. Here, we apply an in vivo metabolic labeling strategy to study their biodistributions
and Ldt-induced bacterial responses to β-lactams in the mouse
gut microbiota. A tetrapeptide-based fluorescent probe that functions
as a substrate for Ldts in Gram-positive bacteria efficiently labels
∼18% of total gut bacteria after gavage, suggesting Ldts’
high prevalence in gut microbiota. The cellular distributions of 3–3
cross-links on three gut bacterial species were then identified with
the aid of fluorescence in situ hybridization to
identify the bacterial taxa. After oral administration of two β-lactams,
ampicillin and meropenem, only the latter efficiently inhibits the
tetrapeptide labeling, suggesting that Ldts may be able to cause resistance
to some β-lactams in the mammalian gut.